(Q33870806)

29 July 2017

1 reference

title

Gene therapy: designer promoters for tumour targeting (English)

1 reference

29 July 2017

0 references

0 references

Nettelbeck DM

1

1 reference

PubMed ID

10729833

29 July 2017

Jérôme V

series ordinal

2

1 reference

PubMed ID

10729833

29 July 2017

Müller R

series ordinal

3

1 reference

29 July 2017

1 April 2000

1 reference

29 July 2017

1 reference

29 July 2017

16

1 reference

29 July 2017

174-181

1 reference

29 July 2017

4

1 reference

29 July 2017

Gene therapy for cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0168-9525%2899%2901950-2

7 January 2021

Tissue-specific gene expression from Mo-MLV retroviral vectors with hybrid LTRs containing the murine tyrosinase enhancer/promoter

1 reference

https://api.crossref.org/works/10.1016%2FS0168-9525%2899%2901950-2

7 January 2021

Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0168-9525%2899%2901950-2

7 January 2021

In vivo gene therapy for prostate cancer: preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors

1 reference

https://api.crossref.org/works/10.1016%2FS0168-9525%2899%2901950-2

7 January 2021

A Potential Approach for Gene Therapy Targeting Hepatoma Using a Liver-Specific Promoter on a Retroviral Vector

1 reference

https://api.crossref.org/works/10.1016%2FS0168-9525%2899%2901950-2

7 January 2021

Endothelial proliferation in tumours and normal tissues: Continuous labelling studies

1 reference

https://api.crossref.org/works/10.1016%2FS0168-9525%2899%2901950-2

7 January 2021

Endothelial cell-specific expression of tumor necrosis factor-alpha from the KDR or E-selectin promoters following retroviral delivery

1 reference

https://api.crossref.org/works/10.1016%2FS0168-9525%2899%2901950-2

7 January 2021

Cell type specificity of the human endoglin promoter

1 reference

https://api.crossref.org/works/10.1016%2FS0168-9525%2899%2901950-2

7 January 2021

Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-9525%2899%2901950-2

7 January 2021

In vitro and in vivo hepatoma cell-specific expression of a gene transferred with an adenoviral vector

1 reference

https://api.crossref.org/works/10.1016%2FS0168-9525%2899%2901950-2

7 January 2021

Adenovirus-mediated gene therapy of gastric carcinoma using cancer-specific gene expression in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0168-9525%2899%2901950-2

7 January 2021

Tumor cell-specific transgene expression prevents liver toxicity of the adeno-HSVtk/GCV approach

1 reference

https://api.crossref.org/works/10.1016%2FS0168-9525%2899%2901950-2

7 January 2021

Effective and safe gene therapy for colorectal carcinoma using the cytosine deaminase gene directed by the carcinoembryonic antigen promoter

1 reference

https://api.crossref.org/works/10.1016%2FS0168-9525%2899%2901950-2

7 January 2021

Targeting gene expression to hypoxic tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0168-9525%2899%2901950-2

7 January 2021

Specific membrane receptor gene expression targeted with radiolabeled peptide employing the erbB-2 and DF3 promoter elements in adenoviral vectors

1 reference

https://api.crossref.org/works/10.1016%2FS0168-9525%2899%2901950-2

7 January 2021

Insulation of a conditionally expressed transgene in an adenoviral vector

1 reference

https://api.crossref.org/works/10.1016%2FS0168-9525%2899%2901950-2

7 January 2021

Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter

1 reference

https://api.crossref.org/works/10.1016%2FS0168-9525%2899%2901950-2

7 January 2021

Regulated expression of the diphtheria toxin A chain by a tumor-specific chimeric transcription factor results in selective toxicity for alveolar rhabdomyosarcoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0168-9525%2899%2901950-2

7 January 2021

Use of Epstein-Barr virus nuclear antigen-1 in targeted therapy of EBV-associated neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0168-9525%2899%2901950-2

7 January 2021

Epstein-Barr virus-driven gene therapy for EBV-related lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0168-9525%2899%2901950-2

7 January 2021

Spatial and temporal control of gene therapy using ionizing radiation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-9525%2899%2901950-2

7 January 2021

Activation of the radiosensitive EGR-1 promoter induces expression of the herpes simplex virus thymidine kinase gene and sensitivity of human glioma cells to ganciclovir

1 reference

https://api.crossref.org/works/10.1016%2FS0168-9525%2899%2901950-2

7 January 2021

Transgene expression in malignant glioma using a replication-defective adenoviral vector containing the Egr-1 promoter: activation by ionizing radiation or uptake of radioactive iododeoxyuridine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-9525%2899%2901950-2

7 January 2021

Regression of hepatocellular carcinoma in vitro and in vivo by radiosensitizing suicide gene therapy under the inducible and spatial control of radiation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-9525%2899%2901950-2

7 January 2021

Employment of the mdr1 promoter for the chemotherapy-inducible expression of therapeutic genes in cancer gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-9525%2899%2901950-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0168-9525%2899%2901950-2

1 reference

7 January 2021

Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-9525%2899%2901950-2

7 January 2021

Cell cycle regulated promoters for the targeting of tumor endothelium

1 reference

https://api.crossref.org/works/10.1016%2FS0168-9525%2899%2901950-2

7 January 2021

A strategy for enhancing the transcriptional activity of weak cell type-specific promoters.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-9525%2899%2901950-2

7 January 2021

Transcriptional regulatory sequences of carcinoembryonic antigen: identification and use with cytosine deaminase for tumor-specific gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-9525%2899%2901950-2

7 January 2021

Utilization of variant-type of human alpha-fetoprotein promoter in gene therapy targeting for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0168-9525%2899%2901950-2

7 January 2021

Vincristine induction of mutant and wild-type human multidrug-resistance promoters is cell-type-specific and dose-dependent

1 reference

https://api.crossref.org/works/10.1016%2FS0168-9525%2899%2901950-2

7 January 2021

Synthetic muscle promoters: activities exceeding naturally occurring regulatory sequences

1 reference

https://api.crossref.org/works/10.1016%2FS0168-9525%2899%2901950-2

7 January 2021

Selective killing of AFP-positive hepatocellular carcinoma cells by adeno-associated virus transfer of the herpes simplex virus thymidine kinase gene

1 reference

https://api.crossref.org/works/10.1016%2FS0168-9525%2899%2901950-2

7 January 2021

Tissue-specific expression of herpes simplex virus thymidine kinase gene delivered by adeno-associated virus inhibits the growth of human hepatocellular carcinoma in athymic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0168-9525%2899%2901950-2

7 January 2021

Tissue-specific, cell cycle-regulated chimeric transcription factors for the targeting of gene expression to tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0168-9525%2899%2901950-2

7 January 2021

CDF-1, a novel E2F-unrelated factor, interacts with cell cycle-regulated repressor elements in multiple promoters.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-9525%2899%2901950-2

7 January 2021

CDF-1-mediated repression of cell cycle genes targets a specific subset of transactivators

1 reference

https://api.crossref.org/works/10.1016%2FS0168-9525%2899%2901950-2

7 January 2021

A dual specificity promoter system combining cell cycle-regulated and tissue-specific transcriptional control

1 reference

https://api.crossref.org/works/10.1016%2FS0168-9525%2899%2901950-2

7 January 2021

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0168-9525%2899%2901950-2

7 January 2021

Complementary adenoviral vectors for oncolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-9525%2899%2901950-2

7 January 2021

A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0168-9525%2899%2901950-2

7 January 2021

Transcriptional targeting of herpes simplex virus for cell-specific replication

1 reference

https://api.crossref.org/works/10.1016%2FS0168-9525%2899%2901950-2

7 January 2021

Inducible control of gene expression: prospects for gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-9525%2899%2901950-2

7 January 2021

10.1016/S0168-9525(99)01950-2

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10729833